Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2018

01-06-2018 | The Global Epidemic (SH Vermund, Section Editor)

Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk

Authors: Lauren Brinkley-Rubinstein, David Cloud, Ernest Drucker, Nickolas Zaller

Published in: Current HIV/AIDS Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

We reviewed the HIV and opioid literature relevant to harm reduction strategies for those with criminal justice experience.

Recent Findings

Opioid use in the United States has risen at an alarming rate recently. This has led to increased numbers of people who inject drugs, placing new populations at risk for HIV, including those who have criminal justice experience. In recent years, there has been a gradual decrease in the number of individuals under the supervision of the criminal justice system. However, concurrently, there has been a rise in the number of individuals incarcerated in jails in rural counties that are at the center of the current opioid epidemic.

Summary

We provide a number of harm reduction strategies that could be implemented in correctional settings such as access and linkage to medication-assisted treatment, connection to syringe exchange programs and safe injection facilities (where available), and the repackaging of pre-exposure prophylaxis as a harm reduction tool.
Literature
1.
Kaeble D, Glaze L. Correctional populations in the United States, 2015. Washington, DC: Bureau of Justice Statistics; 2016.
2.
Kang-Brown J, Subramanian R. Out of sight: The growth of rural jails in America. New York, NY: Vera Institute of Justice; 2017.
3.
Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2015. HIV Surveillance Report (27).
4.
Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR. 2015;64(26):719–25.PubMedPubMedCentral
5.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releases from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. Plos One. 2009;4:e7558.CrossRefPubMedPubMedCentral
6.
Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 2004. Washington, DC: Bureau of Justice Statistics; 2006.CrossRef
7.
Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.CrossRefPubMedPubMedCentral
8.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(5):592–600.CrossRefPubMedPubMedCentral
9.
Ramaswamy M, Freudenberg N. Sex partnerships, health, and social risks of young men leaving jail: analyzing data from a randomized controlled trial. BMC Public Health. 2010;10(1):689–97. PMCID: PMC2988744CrossRefPubMedPubMedCentral
10.
Milloy MJ, Buxton J, Wood E, Li K, Julio SG, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9:156.CrossRefPubMedPubMedCentral
11.
Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725–31.CrossRefPubMedPubMedCentral
12.
Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.CrossRefPubMedPubMedCentral
13.
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174(5):721–9.CrossRefPubMedPubMedCentral
14.
Iroh PA, Mayo H, Nijhawan AE. The HIV care Cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105:e5–e16.CrossRefPubMedPubMedCentral
15.
Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015;21(1):12–26.CrossRefPubMedPubMedCentral
16.
Texas Christian University Institute of Behavioral Research. TCU drug screen 5 opioid supplement. Fort Worth, TX: TCU; 2017.
17.
Perry AE, Neilson M, Martyn-St James M, Glanville JM, Woodhouse R, Godfrey C, Hewitt C. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev 2015, Issue 6. Art. No.: CD010862.
18.
McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, et al. A randomized trial of methadone initiation prior to release from incarceration. Subst Abuse. 2012;33:19–29.CrossRef
19.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–42.CrossRefPubMedPubMedCentral
20.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91:220–7.CrossRefPubMedPubMedCentral
21.
Brinkley-Rubinstein L, McKenzie M, Macmadu A, Zaller N, Larney S, Dauria E, Rich J. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12-months post-release. Drug Alcohol Depend. 2018.
22.
Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BD, Alexander-Scott N, Boss R, Rich JD. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiat. 2018;75(4):405–7.
23.
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158–70.CrossRefPubMedPubMedCentral
24.
Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, et al. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. 2017;112(6):1036–44.CrossRefPubMedPubMedCentral
25.
Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJS, et al. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29(8):965–73.CrossRefPubMedPubMedCentral
26.
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse. 2011;37(1):12–21.CrossRefPubMed
27.
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–32.CrossRefPubMedPubMedCentral
28.
Springer S, Barbour R, Azar M, Alice FL, Di Paola A. Results of a double blind placebo controlled randomized trial of extended-release naltrexone among HIV+ inmates with alcohol use disorders. The College on Problems of Drug Dependence; 2017 June 17–22; Montréal, Canada; 2017.
29.
Springer S, Barbour R, Azar M, et al. Results of a double blind placebo-controlled randomized trial of extended-release naltrexone among HIV+ inmates with opioid dependence The College on Problems of Drug Dependence; 2017 June 17–22; Montréal, Canada; 2017.
30.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
31.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRefPubMed
32.
Centers for Disease Control and Prevention (CDC). Pre-exposure prophylaxis for the prevention of HIV infection in the United States-2014: A clinical practice guideline. Atlanta, GA: CDC; 2014.
33.
Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, Christopoulos K, Chan PA, Beckwith CG, et al. The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. Curr. HIV/AIDS Rep. 2018;15(2):93–5.
34.
Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104:1441–6.CrossRefPubMed
35.
Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in over- dose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37.CrossRefPubMed
36.
Kerr T, Small W, Moore D, Wood E. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver’s safer injection facility. Int J Drug Policy. 2007;18(1):37–45.CrossRefPubMed
37.
Milloy MJ, Kerr T, Mathias R, Zhang R, Montaner JS, Tyndall M, et al. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse. 2008;34(4):499–509.CrossRefPubMed
38.
Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006;1:13.CrossRefPubMedPubMedCentral
39.
Kerr T, Stoltz JA, Tyndall M, Li K, Zhang R, Montaner J, et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ. 2006;332(7535):220–2.CrossRefPubMedPubMedCentral
40.
Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, et al. Rationale for evaluating North America’s first medically supervised safer- injecting facility. Lancet Infect Dis. 2004;4(5):301–6.CrossRefPubMed
41.
42.
DeBeck K, Kerr T, Bird L, Zhang R, Marsh D, Tyndall M, et al. Injection drug use cessation and use of North America’s first medically supervised safer injecting facility. Drug Alcohol Depend. 2011;113(2–3):172–6.CrossRefPubMed
43.
Kimber J, Dolan K, van Beek I, Hedrich D, Zurhold H. Drug consumption facilities: an update since 2000. Drug Alcohol Rev. 2003;22(2):227–33.CrossRefPubMed
Metadata
Title
Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk
Authors
Lauren Brinkley-Rubinstein
David Cloud
Ernest Drucker
Nickolas Zaller
Publication date
01-06-2018
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2018
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-018-0394-z

Other articles of this Issue 3/2018

Current HIV/AIDS Reports 3/2018 Go to the issue

The Global Epidemic (SH Vermund, Section Editor)

The Policy-Driven HIV Epidemic Among Opioid Users in the Russian Federation

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update

The Global Epidemic (SH Vermund, Section Editor)

Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?

The Global Epidemic (SH Vermund, Section Editor)

Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

Continued Interest and Controversy: Vitamin D in HIV

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits